According to a new Rand Corporation (CA, USA) study, the healthcare systems in some European countries lack the capacity to rapidly move a disease-modifying treatment for Alzheimer’s disease approval into widespread clinical use.

The researchers analyzed the preparedness of the healthcare systems in six European countries – France, Germany, Italy, Spain, Sweden and the UK – to ensure timely diagnosis and treatment of patients if a disease-modifying therapy for Alzheimer’s becomes available.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please Login or Register to view this area.